Direct Inhibition of MmpL3 by Novel Antitubercular Compounds

Wei Li, Casey M. Stevens, Amitkumar N. Pandya, Zbigniew Darzynkiewicz, Pankaj Bhattarai, Weiwei Tong, Mercedes Gonzalez-Juarrero, E. Jeffrey North, Helen I. Zgurskaya, Mary Jackson

Research output: Contribution to journalArticle

Abstract

MmpL3, an essential transporter involved in the export of mycolic acids, is the proposed target of a number of antimycobacterial inhibitors under development. Whether MmpL3 serves as the direct target of these compounds, however, has been called into question after the discovery that some of them dissipated the proton motive force from which MmpL transporters derive their energy. Using a combination of in vitro and whole-cell-based approaches, we here provide evidence that five structurally distinct MmpL3 inhibitor series, three of which impact proton motive force in Mycobacterium tuberculosis, directly interact with MmpL3. Medium- to high-throughput assays based on these approaches were developed to facilitate the future screening and optimization of MmpL3 inhibitors. The promiscuity of MmpL3 as a drug target and the mechanisms through which missense mutations located in a transmembrane region of this transporter may confer cross-resistance to a variety of chemical scaffolds are discussed in light of the exquisite vulnerability of MmpL3, its apparent mechanisms of interaction with inhibitors, and evidence of conformational changes induced both by the inhibitors and one of the most commonly identified resistance mutations in MmpL3.

Original languageEnglish (US)
JournalACS Infectious Diseases
DOIs
StatePublished - Jan 1 2019

Fingerprint

Proton-Motive Force
Mycolic Acids
Missense Mutation
Mycobacterium tuberculosis
Mutation
Pharmaceutical Preparations
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

Li, W., Stevens, C. M., Pandya, A. N., Darzynkiewicz, Z., Bhattarai, P., Tong, W., ... Jackson, M. (2019). Direct Inhibition of MmpL3 by Novel Antitubercular Compounds. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.9b00048

Direct Inhibition of MmpL3 by Novel Antitubercular Compounds. / Li, Wei; Stevens, Casey M.; Pandya, Amitkumar N.; Darzynkiewicz, Zbigniew; Bhattarai, Pankaj; Tong, Weiwei; Gonzalez-Juarrero, Mercedes; North, E. Jeffrey; Zgurskaya, Helen I.; Jackson, Mary.

In: ACS Infectious Diseases, 01.01.2019.

Research output: Contribution to journalArticle

Li, W, Stevens, CM, Pandya, AN, Darzynkiewicz, Z, Bhattarai, P, Tong, W, Gonzalez-Juarrero, M, North, EJ, Zgurskaya, HI & Jackson, M 2019, 'Direct Inhibition of MmpL3 by Novel Antitubercular Compounds', ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.9b00048
Li W, Stevens CM, Pandya AN, Darzynkiewicz Z, Bhattarai P, Tong W et al. Direct Inhibition of MmpL3 by Novel Antitubercular Compounds. ACS Infectious Diseases. 2019 Jan 1. https://doi.org/10.1021/acsinfecdis.9b00048
Li, Wei ; Stevens, Casey M. ; Pandya, Amitkumar N. ; Darzynkiewicz, Zbigniew ; Bhattarai, Pankaj ; Tong, Weiwei ; Gonzalez-Juarrero, Mercedes ; North, E. Jeffrey ; Zgurskaya, Helen I. ; Jackson, Mary. / Direct Inhibition of MmpL3 by Novel Antitubercular Compounds. In: ACS Infectious Diseases. 2019.
@article{8d2d9b860cb34168bd70262012f37e10,
title = "Direct Inhibition of MmpL3 by Novel Antitubercular Compounds",
abstract = "MmpL3, an essential transporter involved in the export of mycolic acids, is the proposed target of a number of antimycobacterial inhibitors under development. Whether MmpL3 serves as the direct target of these compounds, however, has been called into question after the discovery that some of them dissipated the proton motive force from which MmpL transporters derive their energy. Using a combination of in vitro and whole-cell-based approaches, we here provide evidence that five structurally distinct MmpL3 inhibitor series, three of which impact proton motive force in Mycobacterium tuberculosis, directly interact with MmpL3. Medium- to high-throughput assays based on these approaches were developed to facilitate the future screening and optimization of MmpL3 inhibitors. The promiscuity of MmpL3 as a drug target and the mechanisms through which missense mutations located in a transmembrane region of this transporter may confer cross-resistance to a variety of chemical scaffolds are discussed in light of the exquisite vulnerability of MmpL3, its apparent mechanisms of interaction with inhibitors, and evidence of conformational changes induced both by the inhibitors and one of the most commonly identified resistance mutations in MmpL3.",
author = "Wei Li and Stevens, {Casey M.} and Pandya, {Amitkumar N.} and Zbigniew Darzynkiewicz and Pankaj Bhattarai and Weiwei Tong and Mercedes Gonzalez-Juarrero and North, {E. Jeffrey} and Zgurskaya, {Helen I.} and Mary Jackson",
year = "2019",
month = "1",
day = "1",
doi = "10.1021/acsinfecdis.9b00048",
language = "English (US)",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Direct Inhibition of MmpL3 by Novel Antitubercular Compounds

AU - Li, Wei

AU - Stevens, Casey M.

AU - Pandya, Amitkumar N.

AU - Darzynkiewicz, Zbigniew

AU - Bhattarai, Pankaj

AU - Tong, Weiwei

AU - Gonzalez-Juarrero, Mercedes

AU - North, E. Jeffrey

AU - Zgurskaya, Helen I.

AU - Jackson, Mary

PY - 2019/1/1

Y1 - 2019/1/1

N2 - MmpL3, an essential transporter involved in the export of mycolic acids, is the proposed target of a number of antimycobacterial inhibitors under development. Whether MmpL3 serves as the direct target of these compounds, however, has been called into question after the discovery that some of them dissipated the proton motive force from which MmpL transporters derive their energy. Using a combination of in vitro and whole-cell-based approaches, we here provide evidence that five structurally distinct MmpL3 inhibitor series, three of which impact proton motive force in Mycobacterium tuberculosis, directly interact with MmpL3. Medium- to high-throughput assays based on these approaches were developed to facilitate the future screening and optimization of MmpL3 inhibitors. The promiscuity of MmpL3 as a drug target and the mechanisms through which missense mutations located in a transmembrane region of this transporter may confer cross-resistance to a variety of chemical scaffolds are discussed in light of the exquisite vulnerability of MmpL3, its apparent mechanisms of interaction with inhibitors, and evidence of conformational changes induced both by the inhibitors and one of the most commonly identified resistance mutations in MmpL3.

AB - MmpL3, an essential transporter involved in the export of mycolic acids, is the proposed target of a number of antimycobacterial inhibitors under development. Whether MmpL3 serves as the direct target of these compounds, however, has been called into question after the discovery that some of them dissipated the proton motive force from which MmpL transporters derive their energy. Using a combination of in vitro and whole-cell-based approaches, we here provide evidence that five structurally distinct MmpL3 inhibitor series, three of which impact proton motive force in Mycobacterium tuberculosis, directly interact with MmpL3. Medium- to high-throughput assays based on these approaches were developed to facilitate the future screening and optimization of MmpL3 inhibitors. The promiscuity of MmpL3 as a drug target and the mechanisms through which missense mutations located in a transmembrane region of this transporter may confer cross-resistance to a variety of chemical scaffolds are discussed in light of the exquisite vulnerability of MmpL3, its apparent mechanisms of interaction with inhibitors, and evidence of conformational changes induced both by the inhibitors and one of the most commonly identified resistance mutations in MmpL3.

UR - http://www.scopus.com/inward/record.url?scp=85064181355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064181355&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.9b00048

DO - 10.1021/acsinfecdis.9b00048

M3 - Article

C2 - 30882198

AN - SCOPUS:85064181355

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

ER -